Dabigatran reversal: Difference between revisions
No edit summary |
No edit summary |
||
| Line 17: | Line 17: | ||
#Consider Recombinant Factor VIIa (no good data) | #Consider Recombinant Factor VIIa (no good data) | ||
#Consider Prothrombin Complex Concentrate (PCC): 50 IU/kg IV bolus (no good data) | #Consider Prothrombin Complex Concentrate (PCC): 50 IU/kg IV bolus (no good data) | ||
==See Also== | |||
*[[Coagulopathy (Main)]] | |||
==Source== | ==Source== | ||
*Hennepin County Guidelines | *Hennepin County Guidelines | ||
*University of Utah Healthcare Thrombosis Service Guidelines | *University of Utah Healthcare Thrombosis Service Guidelines | ||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 14:00, 7 January 2014
Background
- If aPTT is <1.5 x control, it is unlikely that significant drug effect is present
- Thrombin Time (TT) is most sensitive; normal TT excludes presence of significant dabigatran
Mild Bleeding
- Local control measures: direct pressure
- Delay next 1-2 doses OR discontinue (as appropriate)
Moderate-Severe Bleeding
- Local control measures: direct pressure/surgical intervention
- Resuscitate with intravenous fluid and / blood products
- Oral charcoal administration if drug taken <2 hours before presentation
- Hemodialysis will remove ~60% of drug taken over prior 2-3 hours
Life-Threatening Bleeding
All of the above PLUS
- Consider Recombinant Factor VIIa (no good data)
- Consider Prothrombin Complex Concentrate (PCC): 50 IU/kg IV bolus (no good data)
See Also
Source
- Hennepin County Guidelines
- University of Utah Healthcare Thrombosis Service Guidelines